Second-line afatinib vs erlotinib for patients with squamous cell carcinoma of the lung in LUX-Lung 8: analysis of tumor and serum biomarkers

Basit Öğe Kaydı
dc.contributor.authorLee, K. H.
dc.contributor.authorSoria, J-C.
dc.contributor.authorFelip, E.
dc.contributor.authorCobo, M.
dc.contributor.authorLu, S.
dc.contributor.authorSyrigos, K.
dc.contributor.authorGoker, E.
dc.contributor.authorGeorgoulias, V.
dc.contributor.authorLi, W.
dc.contributor.authorGuclu, S.
dc.contributor.authorIsla, D.
dc.contributor.authorArdizzoni, A.
dc.contributor.authorGadgeel, S. M.
dc.contributor.authorDupuis, N.
dc.contributor.authorGibson, N. J.
dc.contributor.authorKramer, N.
dc.contributor.authorBuehnemann, C.
dc.contributor.authorSolca, F.
dc.contributor.authorEhrnrooth, E.
dc.contributor.authorGoss, G.
dc.date.accessioned2019-10-27T11:23:33Z
dc.date.available2019-10-27T11:23:33Z
dc.date.issued2016
dc.departmentEge Üniversitesien_US
dc.description.sponsorshipBoehringer IngelheimBoehringer Ingelheimen_US
dc.description.sponsorshipBoehringer Ingelheimen_US
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.urihttps://hdl.handle.net/11454/33187
dc.identifier.volume27en_US
dc.identifier.wosWOS:000393980600445en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherOxford Univ Pressen_US
dc.relation.ispartofAnnals of Oncologyen_US
dc.relation.publicationcategoryKonferans Öğesi - Uluslararası - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.titleSecond-line afatinib vs erlotinib for patients with squamous cell carcinoma of the lung in LUX-Lung 8: analysis of tumor and serum biomarkersen_US
dc.typeConference Objecten_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu